ACM
KLRS

ADAR1 Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

ADAR1 Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$407K Hold
100,000
– – 0.02% 223
2026
Q1 		$577K Hold
100,000
– – 0.03% 195
2025
Q4 		$844K Buy
+100,000
New +$639K 0.06% 145

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ADAR1 Capital Management's KLRS Position: Q2 2026 in Review

ADAR1 Capital Management held its Kalaris Therapeutics (KLRS) position steady in Q2 2026 at 100,000 shares worth $407K. The position accounts for 0.02% of the portfolio, ranked #223.

ADAR1 Capital Management first reported a position in KLRS in Q4 2025 and has held it in 3 quarters since. The position peaked at $844K in Q4 2025. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • ADAR1 Capital Management held 100,000 shares of Kalaris Therapeutics worth $407K as of Q2 2026.
  • ADAR1 Capital Management left its Kalaris Therapeutics share count unchanged in Q2 2026.
  • Kalaris Therapeutics made up 0.02% of ADAR1 Capital Management's portfolio in Q2 2026, its #223 holding.
  • ADAR1 Capital Management first reported a position in Kalaris Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • ADAR1 Capital Management's Kalaris Therapeutics position peaked at $844K in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.